(Q37866540)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21502281%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

review article

1 reference

title

Evolutionary pathways of transmitted drug-resistant HIV-1 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21502281%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

0 references

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21502281%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

author name string

Monique Nijhuis

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21502281%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Johan A de Bruijn

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21502281%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Charles A B Boucher

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21502281%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Annemarie M J Wensing

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21502281%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

language of work or name

English

0 references

publication date

18 April 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21502281%20AND%20SRC:MED&resulttype=core&format=json

Journal of Antimicrobial Chemotherapy

29 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21502281%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

volume

66

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21502281%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21502281%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

page(s)

1467-1480

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21502281%20AND%20SRC:MED&resulttype=core&format=json

Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda

29 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR157

Could widespread use of combination antiretroviral therapy eradicate HIV epidemics?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR157

The prevalence of antiretroviral drug resistance in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR157

Acute HIV infection: impact on the spread of HIV and transmission of drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR157

Transmission of HIV-1 during primary infection: relationship to sexual risk and sexually transmitted infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR157

High rates of forward transmission events after acute/early HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR157

Transmission of drug-resistant HIV-1 is stabilizing in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR157

Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR157

The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR157

Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR157

Time trends in primary HIV-1 drug resistance among recently infected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR157

Antiretroviral-drug resistance among patients recently infected with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR157

Transmitted drug resistance in persons with acute/early HIV-1 in San Francisco, 2002-2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR157

Rapid accumulation of nonnucleoside reverse transcriptase inhibitor-associated resistance: evidence of transmitted resistance in rural South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR157

Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR157

Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR157

The impact of maternal highly active antiretroviral therapy and short-course combination antiretrovirals for prevention of mother-to-child transmission on early infant infection rates at the Mulago national referral hospital in Kampala, Uganda, Janu

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR157

Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR157

Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR157

Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR157

Prolonged retention of drug resistance mutations and rapid disease progression in the absence of therapy after primary HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR157

Persistence of primary drug resistance among recently HIV-1 infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR157

Long-term persistence of primary genotypic resistance after HIV-1 seroconversion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR157

HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR157

Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR157

Persistence of a sexually transmitted highly resistant HIV-1: pol quasispecies evolution over 33 months in the absence of treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR157

Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR157

Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR157

Progressive reversion of human immunodeficiency virus type 1 resistance mutations in vivo after transmission of a multiply drug-resistant virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR157

Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR157

A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR157

Prevalence of C-terminal gag cleavage site mutations in HIV from therapy-naïve patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR157

Transmembrane protein polymorphisms and resistance to T-20 (Enfuvirtide, Fuzeon) in HIV-1 infected therapy-naive seroconverters and AIDS patients under HAART-T-20 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR157

Transmission of integrase strand-transfer inhibitor multidrug-resistant HIV-1: case report and response to raltegravir-containing antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR157

HIV rebounds from latently infected cells, rather than from continuing low-level replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR157

Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR157

HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR157

HIV protease resistance and viral fitness

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR157

Clinical significance of human immunodeficiency virus type 1 replication fitness

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR157

The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR157

Competitive fitness of nevirapine-resistant human immunodeficiency virus type 1 mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR157

Persistence of HIV-1 variants with multiple protease inhibitor (PI)-resistance mutations in the absence of PI therapy can be explained by compensatory fixation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR157

An increase in viral replicative capacity drives the evolution of protease inhibitor-resistant human immunodeficiency virus type 1 in the absence of drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR157

The effect of transmitted HIV-1 drug resistance on pre-therapy viral load

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR157

Impact of transmission of drug-resistant HIV on the course of infection and the treatment success. Data from the German HIV-1 Seroconverter Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR157

Characterization of the patterns of drug-resistance mutations in newly diagnosed HIV-1 infected patients naïve to the antiretroviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR157

Prevalence of transmitted drug resistance and impact of transmitted resistance on treatment success in the German HIV-1 Seroconverter Cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR157

Primary HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR157

No response to first-line tenofovir+lamivudine+efavirenz despite optimization according to baseline resistance testing: Impact of resistant minority variants on efficacy of low genetic barrier drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR157

Use of peripheral blood DNA for genotype antiretroviral resistance testing in drug-naive HIV-infected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR157

Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR157

Evidence for differences in the sexual transmission efficiency of HIV strains with distinct drug resistance genotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR157

Detection of human immunodeficiency virus (HIV) type 1 M184V and K103N minority variants in patients with primary HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR157

Cellular immune responses to HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR157

Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR157

Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR157

Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR157